Institutional members access full text with Ovid®

Share this article on:

Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?

Gauglitz, Gerd Ga,*; Williams, Felicia Nb,*; Herndon, David Nb,c; Jeschke, Marc Gd

Current Opinion in Clinical Nutrition & Metabolic Care: March 2011 - Volume 14 - Issue 2 - p 176–181
doi: 10.1097/MCO.0b013e3283428df1
Nutrition and the intensive care unit: Edited by Mette Berger and Jeffrey I. Mechanick

Purpose of review The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn.

Recent findings At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy.

Summary Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.

aDepartment of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany

bShriners Hospitals for Children, USA

cDepartment of Surgery, University of Texas Medical Branch, Galveston, Texas, USA

dDepartment of Surgery, Division of Plastic Surgery, University of Toronto, Sunnybrook Research Institute, Toronto, Ontario, Canada

*Gerd G. Gauglitz and Felicia N. Williams contributed equally to the writing of this article.

Correspondence to Associate Professor Marc G. Jeschke, MD, PhD, Department of Surgery, Division of Plastic Surgery University of Toronto, Senior Scientist Sunnybrook Research Institute Rm D704, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada Tel: +1 416 480 6703; fax: +1 416 480 6763; e-mail:

© 2011 Lippincott Williams & Wilkins, Inc.